Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites

Journal of the National Medical Association

Volumn 99, Issue 7, 2007, Pages 718-722

  Hoyo, Cathrine ^a,c   Grubber, Janet ^c   Demark Wahnefried, Wendy ^a   Marks, Jeffrey R ^a   Freedland, Stephen J ^a,d   Jeffreys, Amy S ^d   Grambow, Steven C ^a,d   Wenham, Robert M ^b   Walther, Philip J ^a,d   Schildkraut, Joellen M ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Gleason score; Polymorphisms; Prostate cancer; Race ethnicity

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

AFRICAN AMERICAN; ARTICLE; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; ETHNICITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RACE DIFFERENCE;

ADULT; AFRICAN AMERICANS; AGED; ALLELES; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 34447522001     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Powell IJ, Schwartz K, Hussain M. Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology. 1995;46:825-830.
2. Delfino RJ, Ferrini RL, Taylor TH, et al. Demographic differences in prostate cancer incidence and stage: an examination of population diversity in California. Am J Prev Med. 1998;14:96-102.
3. Moul JW, Douglas TH, McCarthy WF, et al. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 1996;155:1667-1673.
4. Vollmer RT. Race and the linkage between serum prostate-specific antigen and prostate cancer: a study of American veterans. Am J Clin Pathol. 2004;122:338-344.
5. 19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev. 2005;14:403-408.
6. Tsuchiya N, Wang L, Horikawa Y, et al. CA repeat polymorphism in the insulin-like growth factor-1 gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol. 2005;26:225-231.
7. Tsuchiya N, Wang L, Suzuki H, et al. Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol. 2006;24:1982-1989.
8. Neuhausen SL, Slattery ML, Garner CP, et al. Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: strong association of IRS1 G972R variant and cancer risk. Prostate. 2005;64:168-174.
9. Friedrichsen DM, Hawley S, Shu J, et al. IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate. 2005;65:44-51.
10. Li L, Cicek MS, Casey G, et al. No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:497-498.
11. Kimura G, Kasuya J, Giannini S, et al. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int J Urol. 1996;3:39-46.
12. Kaplan PJ, Mohan S, Cohen P, et al. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res. 1999;59:2203-2209.
13. Rosen CJ, Kurland ES, Vereault D, et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab. 1998;83:2286-2290.
14. Rietveld I, Janssen JA, van Rossum EF et al. A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. Clin Endocrinol (Oxf). 2004;61:195-203.
15. Jernstrom H, Chu W, Vesprini D, et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab. 2001;72:144-154.
16. Morimoto LM, Newcomb PA, White E, et al. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: personal and lifestyle factors (United States). Cancer Causes Control. 2005;16:917-927.
17. Allen NE, Davey GK, Key TJ, et al. Serum insulin-like growth factor I (IGF-I) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-I gene. Cancer Epidemiol Biomarkers Prev. 2002;11:319-320.
18. Jernstrom H, Deal C, Wilkin F, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev. 2001;10:377-384.
19. Wang L, Habuchi T, Tsuchiya N, et al. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res. 2003;63:4407-4411.
20. Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005;14:1262-1269.
21. Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:63-69.
22. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab. 2001;86:1274-1280.
23. Lai JH, Vesprini D, Zhang W, et al. A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev. 2004;13:573-582.
24. Schemhammer ES, Hankinson SE, Hunter DJ, et al. Polymorphic variation at the -202 locus in IGFBP3: influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer. 2003;107:60-64.
25. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 2000;92:1910-1917.
26. Chan JM, Stampfer M J, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2002;94:1099-1106.
27. Li L, Yu H, Schumacher F, et al. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control. 2003;14:721-726.
28. Chen C, Lewis SK, Voigt L, et al. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer. 2005;103:76-84.
29. Shariat SF, Lamb DJ, Kattan MW, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002;20:833-841.
30. Platz EA, Pollak MN, Leitzmann MF, et al. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005;16(3):255-262.